Main content area

Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method

Kotwal, Pankul, Magotra, Asmita, Dogra, Ashish, Sharma, Sumit, Gour, Abhishek, Bhatt, Shipra, Wazir, Priya, Singh, Parvinder Pal, Singh, Gurdarshan, Nandi, Utpal
Journal of chromatography 2019
Mycobacterium tuberculosis, World Health Organization, adverse effects, ciprofloxacin, cytochrome P-450, diarylquinolines, drug interactions, drug resistance, fluconazole, guidelines, isoniazid, laboratory animals, liquid chromatography, mechanism of action, models, pharmacokinetics, rats, tandem mass spectrometry, tuberculosis, verapamil
A continuous effort has been given to find out a new drug that is effective against tuberculosis (TB) from both susceptible and resistant strains of Mycobacterium tuberculosis. Bedaquiline represents a recently approved anti-TB drug, which has a unique mechanism of action to fight against multi drug resistance (MDR). Some severe side effects and drug-drug interactions are associated with the treatment of bedaquiline. Moreover, World Health Organisation (WHO) has also been provided guidelines in the year of 2013 for the use of bedaquiline and encourages additional investigation into it. Hence, the pharmacokinetics of bedaquiline upon coadministration with the drug has to be explored in the preclinical model and for which a liquid chromatography tandem mass spectrometry (LC-MS/MS) based bioanalytical method for quantitation of bedaquiline will be useful. A simple, sensitive and rapid LC-MS/MS method was developed, validated and successfully applied to drug interactions of bedaquiline upon coadministration with cytochrome P450 3A4 (CYP3A4) inducers/inhibitors orally in Wistar rats. Results reveal that ciprofloxacin and fluconazole have marked effect to hinder the pharmacokinetics of bedaquiline but isoniazid, verapamil and carbamazepine have on significant effect on bedaquiline pharmacokinetics. Overall, this new bioanalytical method for estimation of bedaquiline in rat plasma was found to be helpful to assess the pharmacokinetics of bedaquiline and very much useful for evaluation of preclinical drug-drug interaction before considering costly and perilous clinical exploration.